JP2018506961A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018506961A5 JP2018506961A5 JP2017532709A JP2017532709A JP2018506961A5 JP 2018506961 A5 JP2018506961 A5 JP 2018506961A5 JP 2017532709 A JP2017532709 A JP 2017532709A JP 2017532709 A JP2017532709 A JP 2017532709A JP 2018506961 A5 JP2018506961 A5 JP 2018506961A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- seq
- domain
- axl
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 9
- 239000000203 mixture Substances 0.000 claims 5
- 210000004408 hybridoma Anatomy 0.000 claims 4
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 3
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 3
- 239000000427 antigen Substances 0.000 claims 3
- 102000036639 antigens Human genes 0.000 claims 3
- 108091007433 antigens Proteins 0.000 claims 3
- 210000004027 cell Anatomy 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 230000002062 proliferating effect Effects 0.000 claims 2
- 108020003175 receptors Proteins 0.000 claims 2
- 102000005962 receptors Human genes 0.000 claims 2
- 108090000790 Enzymes Proteins 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 206010016654 Fibrosis Diseases 0.000 claims 1
- 101150022345 GAS6 gene Proteins 0.000 claims 1
- 101000973901 Homo sapiens Tyrosine-protein kinase Mer Proteins 0.000 claims 1
- 229940123309 Immune checkpoint modulator Drugs 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 241000288906 Primates Species 0.000 claims 1
- 108010003723 Single-Domain Antibodies Proteins 0.000 claims 1
- 101150098329 Tyro3 gene Proteins 0.000 claims 1
- 230000000259 anti-tumor effect Effects 0.000 claims 1
- 108010023337 axl receptor tyrosine kinase Proteins 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000030833 cell death Effects 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 238000011257 definitive treatment Methods 0.000 claims 1
- 238000000375 direct analysis in real time Methods 0.000 claims 1
- 230000007783 downstream signaling Effects 0.000 claims 1
- 238000012063 dual-affinity re-targeting Methods 0.000 claims 1
- 230000004761 fibrosis Effects 0.000 claims 1
- 102000045684 human MERTK Human genes 0.000 claims 1
- 229940127121 immunoconjugate Drugs 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 238000012986 modification Methods 0.000 claims 1
- 230000004048 modification Effects 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000033300 receptor internalization Effects 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
- 231100000765 toxin Toxicity 0.000 claims 1
- 230000004614 tumor growth Effects 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021033363A JP2021101707A (ja) | 2014-12-18 | 2021-03-03 | 抗Ａｘｌアンタゴニスト抗体 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB201422605 | 2014-12-18 | ||
| GB1422605.4 | 2014-12-18 | ||
| PCT/EP2015/080654 WO2016097370A2 (en) | 2014-12-18 | 2015-12-18 | Anti-axl antagonistic antibodies |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021033363A Division JP2021101707A (ja) | 2014-12-18 | 2021-03-03 | 抗Ａｘｌアンタゴニスト抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018506961A JP2018506961A (ja) | 2018-03-15 |
| JP2018506961A5 true JP2018506961A5 (enExample) | 2019-01-24 |
| JP6931609B2 JP6931609B2 (ja) | 2021-09-08 |
Family
ID=55080088
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017532709A Expired - Fee Related JP6931609B2 (ja) | 2014-12-18 | 2015-12-18 | 抗Ａｘｌアンタゴニスト抗体 |
| JP2021033363A Pending JP2021101707A (ja) | 2014-12-18 | 2021-03-03 | 抗Ａｘｌアンタゴニスト抗体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021033363A Pending JP2021101707A (ja) | 2014-12-18 | 2021-03-03 | 抗Ａｘｌアンタゴニスト抗体 |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US10208121B2 (enExample) |
| EP (1) | EP3233119A2 (enExample) |
| JP (2) | JP6931609B2 (enExample) |
| KR (1) | KR102453227B1 (enExample) |
| CN (2) | CN107531786B (enExample) |
| AU (1) | AU2015366213B2 (enExample) |
| CA (1) | CA2969879A1 (enExample) |
| MX (1) | MX390849B (enExample) |
| WO (1) | WO2016097370A2 (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201410826D0 (en) | 2014-06-18 | 2014-07-30 | Bergenbio As | Anti-axl antibodies |
| GB201410825D0 (en) * | 2014-06-18 | 2014-07-30 | Bergenbio As | Anti-axl antibodies |
| EP3233119A2 (en) | 2014-12-18 | 2017-10-25 | Bergen Teknologioverforing AS | Anti-axl antagonistic antibodies |
| GB201506411D0 (en) | 2015-04-15 | 2015-05-27 | Bergenbio As | Humanized anti-axl antibodies |
| GB201509338D0 (en) | 2015-05-29 | 2015-07-15 | Bergenbio As | Combination therapy |
| GB201610902D0 (en) * | 2016-06-22 | 2016-08-03 | Bergen Teknologioverforing As And Bergenbio As | Anti-Axl Antagonistic Antibodies |
| CA3070342A1 (en) * | 2017-07-18 | 2019-01-24 | Kyowa Kirin Co., Ltd. | Anti-human ccr1 monoclonal antibody |
| EP3774904A1 (en) * | 2018-04-10 | 2021-02-17 | Genmab A/S | Axl-specific antibodies for cancer treatment |
| US20210215697A1 (en) | 2018-05-14 | 2021-07-15 | Bergenbio Asa | Serum Biomarkers |
| CN110540592B (zh) * | 2018-05-29 | 2022-08-09 | 杭州尚健生物技术有限公司 | 结合axl蛋白的抗体及其应用 |
| CN109206489A (zh) * | 2018-09-29 | 2019-01-15 | 未名生物医药有限公司 | 蛋白序列12g12及其用途 |
| CN109206490A (zh) * | 2018-09-29 | 2019-01-15 | 未名生物医药有限公司 | 蛋白序列11b09及其用途 |
| US12331320B2 (en) | 2018-10-10 | 2025-06-17 | The Research Foundation For The State University Of New York | Genome edited cancer cell vaccines |
| EP3946453A4 (en) * | 2019-03-29 | 2022-12-07 | Celldex Therapeutics, Inc. | ANTI-AXL ANTIBODIES AND THEIR METHODS OF USE |
| GB201912059D0 (en) | 2019-08-22 | 2019-10-09 | Bergenbio As | Combaination therapy of a patient subgroup |
| WO2021154156A1 (en) * | 2020-01-31 | 2021-08-05 | Agency For Science, Technology And Research | Anti-axl antibody and uses thereof |
| BR112022015977A2 (pt) | 2020-02-28 | 2022-10-11 | Symphogen As | Anticorpos anti-axl e composições |
| GB202004189D0 (en) | 2020-03-23 | 2020-05-06 | Bergenbio As | Combination therapy |
| IL297132A (en) | 2020-04-08 | 2022-12-01 | Bergenbio Asa | axl inhibitors for antiviral therapy |
| GB202006072D0 (en) | 2020-04-24 | 2020-06-10 | Bergenbio Asa | Method of selecting patients for treatment with cmbination therapy |
| JP2024500847A (ja) | 2020-12-18 | 2024-01-10 | センチュリー セラピューティクス，インコーポレイテッド | 適合可能な受容体特異性を有するキメラ抗原受容体システム |
| MX2023008744A (es) | 2021-01-29 | 2023-10-02 | Illimis Therapeutics Inc | Molecula de fusion que tiene actividad no inflamatoria inductora de la fagocitosis. |
| GB202104037D0 (en) | 2021-03-23 | 2021-05-05 | Bergenbio Asa | Combination therapy |
| EP4357365A4 (en) * | 2021-06-16 | 2025-06-04 | Shanghai Sinobay Biotechnology Co., Ltd. | Antibodies against AXL protein and antigen-binding fragment thereof, as well as methods of production and use thereof |
| CN121263449A (zh) * | 2023-03-21 | 2026-01-02 | 拜格拉夫55公司 | Cd19/cd38多特异性抗体 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1382969A1 (en) | 2002-07-17 | 2004-01-21 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Diagnosis and prevention of cancer cell invasion |
| KR101672664B1 (ko) * | 2003-07-21 | 2016-11-04 | 이뮤노젠 아이엔씨 | 인간화된 항체 또는 그의 항원결정기 결합절편 |
| CA2705164A1 (en) * | 2007-11-12 | 2009-05-22 | U3 Pharma Gmbh | Axl antibodies |
| KR101568051B1 (ko) * | 2007-11-15 | 2015-11-10 | 추가이 세이야쿠 가부시키가이샤 | Ａｎｅｘｅｌｅｋｔｏ에 결합하는 단일클론항체, 및 그의 이용 |
| JP5909442B2 (ja) | 2009-05-11 | 2016-04-26 | ユー３・ファーマ・ゲーエムベーハー | ヒト化ａｘｌ抗体 |
| TW201106972A (en) | 2009-07-27 | 2011-03-01 | Genentech Inc | Combination treatments |
| CA2794731C (en) | 2010-06-18 | 2019-03-19 | Genentech, Inc. | Anti-axl antibodies and methods of use |
| EP2596136B1 (en) | 2011-05-06 | 2014-07-16 | Zhongshan Hospital Fudan University | Marker consisting of plasma microrna and new method for diagnosis of hepatocellular carcinoma |
| JP6033293B2 (ja) | 2011-06-22 | 2016-11-30 | インサーム（インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル）Ｉｎｓｅｒｍ（Ｉｎｓｔｉｔｕｔ Ｎａｔｉｏｎａｌ Ｄｅｌａ Ｓａｎｔｅ Ｅｔ Ｄｅ Ｌａ Ｒｅｃｈｅｒｃｈｅ Ｍｅｄｉｃａｌｅ） | 抗Ａｘｌ抗体及びその使用 |
| US9409988B2 (en) | 2011-06-22 | 2016-08-09 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Anti-Axl antibodies and uses thereof |
| EP2589609A1 (en) * | 2011-11-03 | 2013-05-08 | Pierre Fabre Medicament | Antigen binding protein and its use as addressing product for the treatment of cancer |
| US9879061B2 (en) * | 2011-12-15 | 2018-01-30 | The Board Of Trustees Of The Leland Stanford Junior University | Inhibition of AXL/GAS6 signaling in the treatment of liver fibrosis |
| EP2868644B1 (en) | 2012-06-29 | 2018-08-01 | Mitsubishi Gas Chemical Company, Inc. | Method and apparatus for separating alkyl aromatic hydrocarbon |
| CA2890265C (en) * | 2012-11-05 | 2023-01-17 | Pierre Fabre Medicament | Antigen binding proteins and their use as addressing product for the treatment of cancer |
| GB201410826D0 (en) * | 2014-06-18 | 2014-07-30 | Bergenbio As | Anti-axl antibodies |
| GB201410825D0 (en) * | 2014-06-18 | 2014-07-30 | Bergenbio As | Anti-axl antibodies |
| US9986723B2 (en) * | 2014-10-22 | 2018-06-05 | The Board Of Regents Of The University Of Texas System | Screen and use of therapeutics for pancreatic ductal adenocarcinoma |
| EP3233119A2 (en) * | 2014-12-18 | 2017-10-25 | Bergen Teknologioverforing AS | Anti-axl antagonistic antibodies |
| GB201610902D0 (en) * | 2016-06-22 | 2016-08-03 | Bergen Teknologioverforing As And Bergenbio As | Anti-Axl Antagonistic Antibodies |
-
2015
- 2015-12-18 EP EP15822930.2A patent/EP3233119A2/en not_active Withdrawn
- 2015-12-18 CA CA2969879A patent/CA2969879A1/en active Pending
- 2015-12-18 MX MX2017007941A patent/MX390849B/es unknown
- 2015-12-18 WO PCT/EP2015/080654 patent/WO2016097370A2/en not_active Ceased
- 2015-12-18 CN CN201580069347.4A patent/CN107531786B/zh not_active Expired - Fee Related
- 2015-12-18 KR KR1020177018063A patent/KR102453227B1/ko active Active
- 2015-12-18 JP JP2017532709A patent/JP6931609B2/ja not_active Expired - Fee Related
- 2015-12-18 CN CN202211672522.7A patent/CN116410318A/zh active Pending
- 2015-12-18 US US15/533,049 patent/US10208121B2/en active Active
- 2015-12-18 AU AU2015366213A patent/AU2015366213B2/en not_active Ceased
-
2018
- 2018-12-19 US US16/224,935 patent/US11584796B2/en active Active
-
2021
- 2021-03-03 JP JP2021033363A patent/JP2021101707A/ja active Pending
-
2023
- 2023-02-17 US US18/170,929 patent/US20230406941A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI854953B (zh) | 抗ｃｄ３抗體及含有該抗體的分子、及其製造方法 | |
| JP2017535257A5 (enExample) | ||
| JP2022177090A5 (enExample) | ||
| JP7785284B2 (ja) | Ｃｄ３８抗体とｉｃａｍ１抗体およびそれらの使用 | |
| JP2017526339A5 (enExample) | ||
| JP2017519501A5 (enExample) | ||
| JP2019201643A5 (enExample) | ||
| JP2017514461A5 (enExample) | ||
| JP2020510422A5 (enExample) | ||
| JP2022533538A5 (enExample) | ||
| JP2015163068A5 (enExample) | ||
| JP2019528677A5 (enExample) | ||
| JP2020514277A5 (enExample) | ||
| JP2013519364A5 (enExample) | ||
| JP2014509835A5 (enExample) | ||
| US20250034273A1 (en) | Composition of multispecific antibodies targeting cadherin-17-expressing tumors and method of making and using thereof | |
| JP2016536342A5 (enExample) | ||
| JP2023540526A5 (enExample) | ||
| JP2021515541A5 (enExample) | ||
| JP2010509931A5 (enExample) | ||
| JP2017521054A5 (enExample) | ||
| JP7679399B2 (ja) | 抗ｆｌｔ３抗体及び組成物 | |
| JP2020534012A5 (enExample) | ||
| JP2020522280A5 (enExample) | ||
| JP2024540148A5 (enExample) |